C000255648 Fees and Costs — iShares BBB-B CLO Active ETF

Data updated: 2026-10-14

The net expense ratio is 0.45%. There are no sales loads or redemption fees. Portfolio turnover was 30%.

C000255648 Fees and Expenses

Annual operating expenses and sales charges of C000255648. Prospectus, as of July 31, 2025.

Annual operating expenses
Management fee0.45%
12b-1 fee0.00%
Other expenses0.00%
Gross expense ratio0.45%
Fee waiver—
Net expense ratio0.45%
Sales charges
Max front load—
Max deferred load—
Redemption fee—

C000255648 Costs Over Time

On $10,000 invested in C000255648, assuming 5% a year before costs, total costs come to $285 over 5 years, cutting the return by 0.47% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).

$10,000 investedSell after 1 yearSell after 3 yearsSell after 5 years
Value before costs$10,500$11,576$12,763
Fund expenses (net expense ratio 0.45%)$47$148$259
Lost growth on money paid in costs$0$7$26
Total costs$47$156$285
Value after costs$10,453$11,421$12,478
Impact on return, per year0.47%0.47%0.47%

C000255648 Trading Costs

Brokerage costs reported on SEC Form N-CEN for the fiscal year ending July 31, 2026.

  • Explicit cost rate (commissions ÷ average net assets): —
  • Total broker commissions: —
  • Bought from dealers (principal trades, not a cost): $89.4M
  • Portfolio turnover (prospectus): 30%

C000255648 Dealer Counterparties

Securities bought directly from dealers (principal trades).

BrokerAmountShare
BlackRock Funds III - BlackRock Cash Funds: Treasury$43.7M56.62%
Goldman Sachs & Co. LLC$7.0M9.07%
RBC Capital Markets, LLC$5.0M6.48%
BofA Securities, Inc.$5.0M6.45%
Citigroup Global Markets Inc.$3.7M4.82%
Deutsche Bank Securities Inc.$3.0M3.90%
Mizuho Securities USA LLC$3.0M3.90%
Barclays Capital Inc.$2.5M3.27%
SG Americas Securities, LLC$2.2M2.91%
CIBC World Markets Corp.$2.0M2.58%

For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.